Murphy Ant, Liu Bozhi, Benton Annaleigh, Gartenhaus Lauren, Hartzler Samuel, Yates Madison E, Alzate Alejandra Romero, Janson Nimod D, Jayasundara Shyaman, Utturkar Sagar, Lanman Nadia A, Kazemian Majid, Hanna Jason A
Department of Biological Sciences, Purdue University, West Lafayette, Indiana.
Purdue Institute for Cancer Research, Purdue University, West Lafayette, Indiana.
bioRxiv. 2025 Jul 17:2025.07.15.664801. doi: 10.1101/2025.07.15.664801.
Angiosarcoma (AS) is a rare and aggressive tumor arising within the endothelium, characterized by a high metastatic rate and poor prognosis. Our prior work established that endothelial loss of , a key enzyme in microRNA (miRNA) processing, drives AS formation in mice, indicating a tumor suppressive role for miRNAs in tumorigenesis. Here, we corroborated this hypothesis by generating a novel conditional knockout model targeting , a core component of the microprocessor complex required for pri-miRNA processing. Conditional deletion of phenocopies loss, resulting in spontaneous AS formation and global loss of mature miRNAs. We further demonstrate that treatment with enoxacin (ENX), a repurposed antibiotic known to enhance miRNA processing, reduces viability, migration, and clonogenicity of AS cells. ENX increases the abundance of tumor-suppressive miRNAs and downregulates oncogenic pathways, including pathways related to cell cycle progression, angiogenesis, and cell migration. These results establish the essential role of miRNA biogenesis in suppressing AS and reveal a pharmacologically targetable vulnerability via ENX-mediated enhancement of miRNA expression in tumors.
血管肉瘤(AS)是一种罕见的侵袭性肿瘤,起源于内皮细胞,其特征是转移率高且预后不良。我们之前的研究表明,作为微小RNA(miRNA)加工中的关键酶,其在内皮细胞中的缺失会驱动小鼠AS的形成,这表明miRNA在肿瘤发生中具有肿瘤抑制作用。在此,我们通过构建一种针对的新型条件性敲除模型来证实这一假设,是初级miRNA(pri-miRNA)加工所需的微处理器复合体的核心组成部分。的条件性缺失模拟了的缺失,导致自发性AS形成和成熟miRNA的整体缺失。我们进一步证明,使用已知可增强miRNA加工的重新利用的抗生素恩诺沙星(ENX)进行治疗,可降低AS细胞的活力、迁移能力和克隆形成能力。ENX增加了肿瘤抑制性miRNA的丰度,并下调了致癌途径,包括与细胞周期进程、血管生成和细胞迁移相关的途径。这些结果确立了miRNA生物合成在抑制AS中的重要作用,并揭示了通过ENX介导的肿瘤中miRNA表达增强而产生的可药物靶向的脆弱性。
Graefes Arch Clin Exp Ophthalmol. 2025-1-6
Nat Rev Mol Cell Biol. 2025-4
Nucleic Acids Res. 2025-1-6
Mol Oncol. 2025-4
Mol Cancer Res. 2024-9-4
Mol Cancer Res. 2024-8-2
JAMA Netw Open. 2024-4-1
Sci Rep. 2023-9-1